Psoriatic Arthritis

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Combination of risk factors and PsA disease activity found increase dangers of cardiovascular disease.

Study suggests superior efficacy from older PsA drugs.

Secukinumab shows promise in the treatment of patients with psoriatic arthritis.

Improvements in itching scores maintained from week 16 to week 52 in patients who received Otezla.

Health information sharing web site helps connect patients among more than 2500 conditions.

Chronic inflammatory skin condition associated with decreased quality of life and increased all-cause mortality.

Lengthening time between treatment with anti-TNF agents may improve adherence.

Mild psoriasis, severe psoriasis, and psoriatic arthritis may also bring increased comorbidities.

Caregivers need to help patients with psoriasis understand the importance of lifestyle behavior choices.

The role of vitamin D in diseases such as psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis.

Psoriasis treatment may improve more than just skin issues.

A 10-second assessment may be as effective as more complex tests.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Lithium chloride found to slow degradation.

Patients who received secukinumab sustained improvements over one year of treatment.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.

Study finds improved screening needed for condition.

Physical aspects and quality of life issues improve with treatment.

Treatment blocks signals that may lead to inflammation.

Amgen has terminated its co-development and commercialization of brodalumab with AstraZeneca after observing suicidal ideation and behavior in clinical trial participants.

Treatment found to improve several measures of disease activity and quality of life in patients with Behçet's disease.

Experimental treatment blocks signaling protein.